Xylem Work in process increased by 9.0% to $109.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.8%, from $111.00M to $109.00M. Over 5 years (FY 2020 to FY 2025), Work in process shows an upward trend with a 15.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.00M | $62.00M | $58.00M | $71.00M | $71.00M | $67.00M | $58.00M | $71.00M | $121.00M | $106.00M | $102.00M | $112.00M | $117.00M | $118.00M | $100.00M | $111.00M | $113.00M | $115.00M | $100.00M | $109.00M |
| QoQ Change | — | +0.0% | -6.5% | +22.4% | +0.0% | -5.6% | -13.4% | +22.4% | +70.4% | -12.4% | -3.8% | +9.8% | +4.5% | +0.9% | -15.3% | +11.0% | +1.8% | +1.8% | -13.0% | +9.0% |
| YoY Change | — | — | — | — | +14.5% | +8.1% | +0.0% | +0.0% | +70.4% | +58.2% | +75.9% | +57.7% | -3.3% | +11.3% | -2.0% | -0.9% | -3.4% | -2.5% | +0.0% | -1.8% |
| % of Inventories | 9.7% | 9.1% | 8.3% | 8.8% | 8.3% | 8.0% | 7.3% | 8.3% | 10.6% | 9.8% | 10.0% | 10.8% | 11.1% | 10.8% | 10.0% | 10.9% | 10.6% | 11.1% | 10.2% | 11.0% |
| Share Change | — | -0.5pp | -0.8pp | +0.5pp | -0.5pp | -0.3pp | -0.7pp | +1.0pp | +2.3pp | -0.8pp | +0.2pp | +0.8pp | +0.3pp | -0.3pp | -0.8pp | +0.8pp | -0.3pp | +0.6pp | -0.9pp | +0.8pp |